Anti‐Programmed death‐1 therapy in advanced hepatocellular carcinoma: A real‐world experience

Anti‐Programmed death‐1 therapy in advanced hepatocellular carcinoma: A real‐world experience

Abstract Nivolumab is an effective and safe treatment in HCC.

Bibliographic Details
Main Authors:	Ouissam Al jarroudi, Hamed Chaabouni, Ayhan Ulusakarya, Wathek Almohamad, Yusuf Gumus, Emma Goldschmidt, Said Afqir, Jean‐francois Morère
Format:	Article
Language:	English
Published:	Wiley 2021-04-01
Series:	Clinical Case Reports
Subjects:	clinical outcomes hepatocellular carcinoma nivolumab survival
Online Access:	https://doi.org/10.1002/ccr3.3970

Similar Items

Real-World Outcomes of Nivolumab in Patients With Unresectable Hepatocellular Carcinoma in an Endemic Area of Hepatitis B Virus Infection
by: Pil Soo Sung, et al.
Published: (2020-06-01)

Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure
by: Yuan-Hung Kuo, et al.
Published: (2021-05-01)

Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment
by: Cheol-Hyung Lee, et al.
Published: (2020-07-01)

Adjuvant Immunotherapy after Curative Treatment for Hepatocellular Carcinoma
by: Masatoshi Kudo
Published: (2021-09-01)

Immunotherapy with Checkpoint Inhibitors for Hepatocellular Carcinoma: Where Are We Now?
by: Francesco Tovoli, et al.
Published: (2020-10-01)

Clinical significance of radiotherapy before and/or during nivolumab treatment in hepatocellular carcinoma
by: Jeong Il Yu, et al.
Published: (2019-11-01)

Immunotherapy for hepatocellular cancer: beginning and future perspectives
by: M. A. Kazantseva, et al.
Published: (2019-06-01)

The safety and efficacy of lenvatinib combined with immune checkpoint inhibitors therapy for advanced hepatocellular carcinoma
by: Yun Wang, et al.
Published: (2020-12-01)

Tumor Lysis Syndrome after Combination Therapy of Nivolumab and Sorafenib in a Woman with Advanced Hepatocellular Carcinoma
by: Tsai-Hung Yen, et al.
Published: (2020-07-01)

A Disintegrin and Metalloproteinase 9 (ADAM9) in Advanced Hepatocellular Carcinoma and Their Role as a Biomarker During Hepatocellular Carcinoma Immunotherapy
by: Sooyeon Oh, et al.
Published: (2020-03-01)

Second-line treatment of hepatocellular carcinoma: from theory to practical issues
by: V. V. Breder, et al.
Published: (2019-12-01)

Emerging Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
by: Vito Longo, et al.
Published: (2019-10-01)

Inexpensive Systemic Inflammatory Biomarkers in Ovarian Cancer: An Umbrella Systematic Review of 17 Prognostic Meta-Analyses
by: Khalid El Bairi, et al.
Published: (2021-09-01)

Ablation Reboots the Response in Advanced Hepatocellular Carcinoma With Stable or Atypical Response During PD-1 Therapy: A Proof-of-Concept Study
by: Ning Lyu, et al.
Published: (2020-10-01)

Nivolumab in Non-Small Cell Lung Cancer: Real World Long-Term Survival Results and Blood-Based Efficacy Biomarkers
by: Sameh Daher, et al.
Published: (2021-07-01)

Immune Checkpoint Inhibitors in the Treatment of HCC
by: Clelia Donisi, et al.
Published: (2021-01-01)

Ovarian cancer in Morocco: Time to act is now
by: Khalid El Bairi, et al.
Published: (2021-08-01)

Tracing ovarian cancer research in Morocco: A bibliometric analysis
by: Khalid El Bairi, et al.
Published: (2021-08-01)

Liver Function and Treatment Modalities are Predictors of Survival in Patients with Hepatocellular Carcinoma
by: Irsan Hasan, et al.
Published: (2020-09-01)

Hepatic Reirradiation for Patients with Recurrent Hepatocellular Carcinoma
by: Yaoru Huang, et al.
Published: (2021-02-01)

Untreated hepatocellular carcinoma in Egypt: outcome and prognostic factors
by: Zeeneldin AA, et al.
Published: (2015-01-01)

Clinical impact of post‐progression survival on overall survival in patients receiving nivolumab monotherapy as a second‐line treatment for advanced non‐small cell lung cancer
by: Hisao Imai, et al.
Published: (2021-04-01)

A mathematical model for exchanging waves between cellular DNA and drug molecules and their roles in curing cancer
by: S.K. Elagan, et al.
Published: (2021-03-01)

Clinical impact of lenvatinib in patients with unresectable hepatocellular carcinoma who received sorafenib
by: Yen-Yang Chen, et al.
Published: (2020-11-01)

Transarterial Chemoembolization Combined with Sorafenib in Patients with BCLC Stage C Hepatocellular Carcinoma
by: Liu KC, et al.
Published: (2020-08-01)

Serum choline is associated with hepatocellular carcinoma survival: a prospective cohort study
by: Zhao-Yan Liu, et al.
Published: (2020-03-01)

Severe Fatigue is an Important Factor in the Prognosis of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib
by: Qiu X, et al.
Published: (2020-09-01)

Clinical Presentation of Hepatocellular Carcinoma in African Americans vs. Caucasians: A Retrospective Analysis
by: Hrishikesh Samant, et al.
Published: (2021-08-01)

Is there a sex difference in postoperative prognosis of hepatocellular carcinoma?
by: Ming-Wei Lai, et al.
Published: (2019-03-01)

The role of scheduled second TACE in early-stage hepatocellular carcinoma with complete response to initial TACE
by: Jung Hee Kim, et al.
Published: (2017-03-01)

Sarcomatoid hepatocellular carcinoma: From clinical features to cancer genome
by: Cheng Zhang, et al.
Published: (2021-09-01)

Results of surgical treatment of hepatocellular carcinoma
by: Adriano Miziara Gonzalez, et al.
Published: (2004-12-01)

Clinical outcomes of patients with a single hepatocellular carcinoma less than 5 cm treated with transarterial chemoembolization
by: Min Young Baek, et al.
Published: (2019-11-01)

The prognostic factors between different viral etiologies among advanced hepatocellular carcinoma patients receiving sorafenib treatment
by: Ming‐Lun Yeh, et al.
Published: (2019-10-01)

Two cases of nonbacterial cystitis associated with nivolumab, the anti-programmed-death-receptor-1 inhibitor
by: Kimihiro Shimatani, et al.
Published: (2018-03-01)

Tailored Prediction Model of Survival after Liver Transplantation for Hepatocellular Carcinoma
by: Indah Jamtani, et al.
Published: (2021-06-01)

Can Immediately Treating Subcentimeter Hepatocellular Carcinoma Improve the Survival of Patients?
by: Sun X, et al.
Published: (2020-12-01)

Expression Pattern and Prognostic Utility of PME-1 in Patients with Hepatocellular Carcinoma
by: Du B, et al.
Published: (2020-04-01)

Immunotherapy in Hepatocellular Carcinoma: Is There a Light at the End of the Tunnel?
by: Amit Mahipal, et al.
Published: (2019-07-01)

Prognostic Value of Serum Osteoprotegerin Level in Patients With Hepatocellular Carcinoma Following Surgical Resection
by: Chihao Zhang, et al.
Published: (2021-09-01)